Johanna Holldack
Director/Board Member at PHOTOCURE ASA
Net worth: - $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Madiha Derouazi | M | 51 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | 12 years |
Erik Dahl | M | - | 12 years | |
Neal Shore | M | - | 2 years | |
Dylan Hallerberg | M | - | - | |
Daniel Schneider | M | - | 6 years | |
Anders Neijber | M | - | 3 years | |
Patricia Kelly | F | - | 4 years | |
Susanne Strauss | M | - | 4 years | |
Andreas Wallnöfer | M | 63 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
Karin Hehenberger | M | 52 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
Pierre Armand Morgon | M | 61 |
Kupando GmbH
Kupando GmbH BiotechnologyHealth Technology Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018. | 3 years |
Malene Brondberg | F | 51 | - | |
Frank Kalkbrenner | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
Grete Hogstad | F | 68 | 19 years | |
Geoffrey Coy | M | - | 5 years | |
Roberto Maj | M | - |
Kupando GmbH
Kupando GmbH BiotechnologyHealth Technology Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018. | - |
Maja Bergmann | F | - | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kjetil Hestdal | M | 64 | 21 years | |
Gwen Melincoff | M | 72 | 3 years | |
Tom Edward Pike | M | 64 | 6 years | |
Jan Hendrik Egberts | M | 65 | 6 years | |
Synne Hermansen Røine | F | 45 | 6 years | |
Anne Hovi Worsøe | F | 60 | - | |
Gry Stensrud | M | 54 | 15 years | |
Anders Tuv | M | 46 | - | |
Jeremy Bahr | M | - | - | |
Kari Myren | F | - | 6 years | |
Einar Antonsen | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Norway | 22 | 78.57% |
Switzerland | 4 | 14.29% |
Germany | 2 | 7.14% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Johanna Holldack
- Personal Network